High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.

View in: PubMed

subject areas

Adult
Aged
Cancer Vaccines
Disease-Free Survival
Female
G(M2) Ganglioside
Hemocyanins
Humans
Immunoglobulin G
Immunoglobulin M
Interferon-alpha
Male
Melanoma
Middle Aged
Neoplasm Staging
Prospective Studies
Recombinant Proteins
Saponins
Vaccination
Vaccines, Conjugate

authors with profiles

JOHN KIRKWOOD